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Abstract
Background: Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent
leading to the establishment of particle therapy in this indication. However, even modern techniques leave space
for improvement of local control by intensification of local treatment. Radiation sensitization by exploitation of
high EGFR-expression in ACC with the EGFR receptor antibody cetuximab seems promising.
Methods/design: The ACCEPT trial is a prospective, mono-centric, phase I/II trial evaluating toxicity (primary
endpoint: acute and late effects) and efficacy (secondary endpoint: local control, distant control, disease-free
survival, overall survival) of the combined treatment with IMRT/carbon ion boost and weekly cetuximab in 49
patients with histologically proven (≥R1-resected, inoperable or Pn+) ACC. Patients receive 18 GyE carbon ions (6
fractions) and 54 Gy IMRT (2.0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy.
Discussion: The primary objective of ACCEPT is to evaluate toxicity and feasibility of cetuximab and particle
therapy in adenoid cystic carcinoma.
Trial Registration: Clinical Trial Identifier: NCT 01192087
EudraCT number: 2010 - 022425 - 15
Background
Adenoid cystic carcinomas are rare tumors mostly of
the head and neck accounting for approximately 10-15%
of malignant salivary gland tumors [1]. They are charac-
terised by a rather slow growth pattern but also peri-
neural spread. Standard treatment so far consists of
preferably complete surgical resection followed by adju-
v a n ti r r a d i a t i o ni nc a s eo fc lose margins, perineural
invasion, extensive primary tumor (T3, T4) or high-
grade histology [2-5].
Local control in this disease could already be
improved high-precision radiotherapy techniques such
as stereotactic radiotherapy and/or intensity-modulated
radiation therapy (IMRT), dose escalation, and high-LET
RT. Treatment of large inoperable or residual tumors
with IMRT resulted in increased local control as com-
pared to conventional RT achieving progression-free
survival rates of 38% at 3 years [6]. Neutron RT with a
local control of 75% at 5 years, so far yielded the highest
control rates in adenoid cystic carcinoma though unfor-
tunately also accompanied by significant late toxicity
[7,8].
Combined IMRT and C12 heavy ion boost are able to
achieve similar or superior control rates as compared to
neutron RT but without increase of late toxicity and
subsequent morbidity. Recent results of our own group
reported local control rates of 78% at 4 years [9] and
82% at 5 years respectively [10,11]. Our results are con-
sistent with outcomes published by Mizoe et al in a
smaller, more inhomogeneous patient cohort [12] lead-
ing to acceptance of our treatment regimen as a stan-
dard in Germany whenever available. Albeit progress
has been made by the introduction of particle therapy in
the treatment concept of adenoid cystic carcinoma, local
control rates still leave room for improvement.
Novel paths have also been struck with radiochemother-
apeutic approaches where various platin-containing
regimen have been tested over the years but have not
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[13-16].
Overall survival is unfortunately still limited by the
occurence of distant metastases [6,17]. In recurrent or pro-
gressive metastatic disease, chemotherapy with cyclopho-
sphamide, doxorubicine, and cisplatin ("CAP”)i sm o s t
commonly used as a therapeutic standard since the mid-
80s [18-20] with response rates between 40 and 64% and
remission rates of up to 24%. However, median duration of
remission is generally only between 5-13 months [17,21].
More recently though, targeted therapies have raised
expectations for the treatment of adenoid cystic carci-
noma [22,23]. In view of high expression of EGF-recep-
tors (up to 90%) in adenoid cystic carcinomas, therapy
with the EGFR- antibody cetuximab seemed promising
[22]. Despite the initial enthusiasm though, treatment
results in recurrent and metastatatic adenoid cystic car-
cinoma have so far failed to impress: no objective
response in recurrent or metastatic adenoid cystic carci-
noma could be shown in any of the trials [24-26]
although prolonged disease stabilization was observed in
the reported series [25,26].
With the publication of the Bonner trial establishing
radioimmunotherapy for squamous cell carcinoma of
the head and neck (SCCHN) [27,28], the synergistic and
radiosensitizing potential of cetuximab in combination
with radiation therapy [29,30] was clinically proven. In
view of the very mild and therefore attractive toxicity
profile, cetuximab is a promising candidate to intensify
local radiation therapy in adenoid cystic carcinoma. The
ACCEPT trial was designed to evaluate toxicity and fea-
sibility of the combination treatment (IMRT and carbon
ion boost) with cetuximab.
Methods/design
Study design
The ACCEPT trial is a prospective, non-randomized
phase II feasibility trial evaluating toxicity (any toxicity ≥
grade 3 CTCAE v. 4) of the combined treatment as pri-
mary endpoint.
Study Characteristics
Combined IMRT and C12-heavy ion boost has previously
been established as a treatment of choice in skull-base
adenoid cystic carcinoma. In order to potentially further
improve local control, the established treatment is comple-
mented by the addition of cetuximab weekly. Therefore,
the combination of IMRT (54 Gy in 2 Gy/fraction) and
C12-boost (18 GyE in 3 GyE/fraction) and weekly Cetuxi-
mab will be tested as to toxicity profile and efficacy.
Study objectives
To evaluate feasibility and toxicity of the combined
treatment with IMRT/carbon ion boost and cetuximab
are primary endpoints by assessing the incidence of any
side effects with CTCAE ≥ grade 3. Secondary endpoints
are local control, distant control, disease-free survival,
and overall survival.
Sample size/number of subjects
The trial design is based on the following assumptions:
￿ The experimental therapy is unacceptable if the true
feasibility rate (:= 1 - withdrawal/dose limiting toxicity
rate) is 70% or lower.
￿ The experimental therapy is considered promising if
the true feasibility rate is 85% or more.
￿ Probability to accept the experimental therapy as
well tolerated despite a true feasibility rate of <70%: 5%
(type I error)
￿ Probability to reject the experimental therapy despite
a true feasibility rate of >85%: 20% (type II error).
According to these parameters and using the variant
out of the class of optimal two-stage designs by Simon
[31] leading to the lowest required patient number,
23 pts evaluable for feasibility have to be recruited in
the first stage. The combination will be rejected if seven
or more of these patients fulfill the criterion of non-
feasibility. Otherwise, further patients will be recruited
in a second stage up to a total number of 49 subjects.
Patient selection
Inclusion criteria
￿ Histologically proven adenoid-cystic carcinoma of the
head and neck and Macroscopic or microscopic tumor
rest (R1/R2) or
￿ Tumor stage >T3/T4 or
￿ perineural invasion and
￿ M0
￿ Written informed consent
￿ Age between 18 and 70 a
￿ Karnofsky-Index ≥ 70%
￿ adequate bone-marrow, liver, and kidney function
￿ effective contraception for patients in procreative age
Exclusion criteria
￿ prior RT or chemotherapy for tumors of the head and
neck
￿ R0-resection
￿ M1 (metastases)
￿ prior immunotherapy
￿ signs of active infection
￿ other serious illnesses or medical conditions:
therapy-refractory unstable heart disease, congestive
heart failure NYHA °III and °IV; coagulopathies
￿ Other previous malignancy within the past 5 years
except prior, adequately treated basal cell carcinoma of
the skin or pre-invasive carcinoma of the cervix
￿ Significant neurological or psychiatric condition
including dementia or seizures or other serious medical
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trial by judgement of the investigators
￿ Legal incapacity or limited legal capacity
￿ Positive serum/urine b-HCG/pregnancy
￿ Drug abuse
Radiotherapy
Immobilisation/planning examinations
Patients are immobilized using individual thermoplastic
head masks with thermoplastic shoulder fixation. Plan-
ning examinations consist of a planning CT scan (3 mm
slice thickness) with the patient positioned in the indivi-
dual fixation device and contrast-enhanced MRI for 3D
image correlation.
Target volumes/dose prescription
CTV1 (carbon ion boost) includes the macroscopic
tumour/prior tumour bed with special focus on the R1-
area as well as respective neural pathways to the base of
skull (cave: perineural invasion and skip lesions). For
tumours of the parotid gland, the whole former parotid
area is also included in the CTV1, if possible the man-
dibular joint is kept outside the CTV1. PTV1 consists of
a 3 mm margin around the CTV1 but does not extend
into critical organs at risk (i.e. brain stem, spinal cord).
We prescribe a dose of 24 GyE carbon ions in 3 GyE/
fraction (5 fractions per week) to the CTV1, we aim at cov-
ering the CTV1 with the 95% prescription isodose. Treat-
ment is given at the HIT (Heidelberg ion therapy centre)
after inverse treatment planning in active beam application
(raster-scanning method). Daily image guidance consists of
orthogonal x-ray controls in treatment position.
CTV2 includes CTV1 with safety margins along typi-
cal pathways of spread. Only ipsilateral nodal levels (II
and III) are includes, however, in case the primary
tumour is/was located at midline or crossing midline,
we cover bilateral nodal levels II and III. In case there is
a pathological lymph node involvement, additional nodal
level will be covered as indicated. CTV2 also encom-
passes the complete surgical operational area. The
CTV2 also takes account for set-up variations, hence
corresponds to the PTV2 (CTV2 = PTV2). Should the
primary tumour be located within the parotid gland,
also the parotid duct needs to be within the CTV2.
50 Gy IMRT (inversely planned step-and-shoot or
tomotherapy technique) in 25 fractions (5 fractions per
week) are prescribed to the CTV2 (coverage at least with
the 90% prescription isodose) taking into account doses
applied by daily image guidance with MV-cone-beam CT.
Immunotherapy
Cetuximab is administered as 400 mg/m2 body surface
loading dose 7 days prior to RT-treatment start (d-7)
after administration of anti-histamines (dimetindene)
and corticosteroids (dexamethasone).
Weekly administrations of Cetuximab 250 mg/m2
body surface follow for the duration of radiotherapy
from d1.
Supportive therapy
Patients do not routinely receive prophylactic feeding
tubes, however if they uncommonly experience signifi-
cant weight loss we will of course offer feeding tube
insertion or parenteral feeding.
Treatment schedule/follow-up
Treatment schedule
After inclusion into the trial and the patient’s written
informed conset, the patient receives an individual posi-
tioning device (aquaplast mask incl. shoulder fixation)
and RT treatment planning scans (CT/MRI). Subse-
quently, patients are administered Cetuximab loading
dose on day -7 (400 mg/m² body surface). On day 1 (wk 1),
the patient receives the first weekly Cetuximab (250 mg/m²
body surface) as well as the first fraction of radiation
therapy (figure 1).
First, the patient receives 6 fractions of C12 heavy ion
boost to the GTV to a total dose of 18 GyE at 3 GyE
per fraction. Subsequently, the patient receives intensi-
tiy-modulated photon radiation therapy (IMRT) to the
CTV to a dose of 54 Gy at 1.8 Gy per fraction (5 frac-
tions per week). Overall, the total dose adds up to
72 GyE in 36 fractions.
Target localisation can either be stereotactically and/or
under image guidance.
Follow-up
First follow-up examination including diagnostic, con-
trast-enhanced MRI will be carried out 6 weeks post
completion of radiation treatment. Further controls
including MRI are 3, 6, and 12 months thereafter, in
6 monthly intervals until 2 years post RT, then in yearly
intervals (figure 2). Abdominal ultrasound will be
carried out q6months, chest-CT q12months. At each
follow-up appointment, patients receive a symptom-
oriented clinical examination, also patients’ performance
state (Karnofsky-Index), therapy-associated side effects
as well as potential intercurrent therapy is recorded.
Patients are also encouraged to undergo regular
check-ups incl. full ENT clinical examinations in regular
intervals.
Trial duration
The trial fort he individual patient is completed after a
3-year follow-up period. Recruitement will p
Assessment of efficacy
Assessment of efficacy will be carried out by evaluation
of imaging studies (MRI) at each follow-up. If applicable
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Figure 2 Trial schedule/follow-up.
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response will be evaluated according to the RECIST-
criteria [32].
Proteomics and Genomics
For the proteomic examinations 30 mL venous blood
will be collected from each subject prior to the first
administration of IMP, at day 8 (before the first irradia-
tion), at completion of the carbon ion boost (typically at
day 14), at completion of radioimmunotherapy (typically
day 54 of the treatment phase) and once at the 1st fol-
low-up visit. Thus, the overall volume of blood samples
used for Proteomic/Genomic investigations will be
approximately 120 mL. Following parameters/pathways
will be investigated:
￿ In order to predict the efficacy of the trimodal
therapy blood will be collceted during therapy and
follow-up to detect and correlate the levels of well
known tumor- and angiogenesis markers (VEGF,
T G F - A l p h a ,b F G F ,I L 8 ,k - r a s ,e t c . )u s i n gE n z y m e -
Linked Immunosorbent Assay (ELISA). Further, pla-
telet protein content (i.e. tumor angiogenesis growth
factors and cytokines) will be analyzed using citrate
b l o o ds a m p l e sa n dc o r r e l a t e dw i t hs e r u m -a n d
plasma- protein results.
￿ In order to perform the genomic analysis,
patients’ blood samples are collected as indicated
and RNA, miRNA and DNA isolation will be per-
formed. Based on an established platform, linear
RNA-amplification, labelling and hybridization on
human genome wide oligo-arrays (transcriptome
analysis) are planned. DNA samples are used to
identify potential chromosomal aberrations or epi-
genetic alterations that might predict treatment
response. RNA and miRNA samples are further
analyzed by real time quantitative RT-PCR to con-
firm microarray data and to test a subset of clinical
predictors.
The determinations of proteomic and genomic para-
meters will be carried out at the Department of Radia-
tion Oncology in Heidelberg.
No further genetic investigations on the blood col-
lected during the study will be carried out!
Trial organization/coordination
The ACCEPT trial has been designed by the Department
of Radiation Oncology, University of Heidelberg, and is
carried out at the Heidelberg Ion Therapy Centre (HIT). It
is an investigator-initiated trial; the Department of Radia-
tion Oncology is responsible for co-ordination, overall trial
management, registration (clinicaltrials.gov Identifier:
NCT 01192087); EudraCT registration (EudraCT number:
2010 - 022425 - 15), database management, quality assur-
ance, monitoring, and reporting is carried out by WiSP
Wissenschaftlicher Service Pharma GmbH, Langenberg,
Germany.
Investigators
Patients are recruited by the Department of Radiation
Oncology, Heidelberg, Germany.
Adverse events
Adverse and serious adverse events are recorded using
NCI common toxicity criteria for adverse events
(CTCAE v. 4). Acute radiation effects are defined as
effects occurring within 90 days from beginning of
radiotherapy. Late effects are defined as effects observed
thereafter. Safety analysis is performed with respect to
frequency of serious adverse events and adverse events
stratified by organ system, severity, causality.
Regular completion of the trial
Patient accrual is completed with inclusion of the last
patient and should extend for approximately 2 years
from trial initiation. Regular trial participation for each
patient terminates 3 years post inclusion into the trial
or the patient’s death respectively.
Discontinuation of treatment
￿ Patient wish
￿ Cetuximab treatment delay for more than 2 conse-
cutive weeks,
￿ Occurrence of any grade 4 toxicities related to
cetuximab,
￿ Occurrence of >/= grade 3 allergic/hypersensitivity
reaction related to cetuximab.
￿ Medical condition necessitating treatment termina-
tion and withdrawal of the patient from the trial
￿ Pregnancy
￿ Lack of compliance
Premature termination of the trial
The trial can be prematurely closed or suspended by the
LKP in following cases:
￿ Medical or ethical reasons relevantly affecting the
risk-benefit relationship,
￿ Difficulties in recruitment of subjects suggest unjus-
tifiable prolongation of the study timeline,
￿ Previously unexpected adverse events (in respect of
their nature, severity, duration or outcome) occur with
unjustifiable frequency,
￿ Expected adverse events occur with an unexpectedly
high incidence,
￿ Relevant superiority of patients in one treatment
arm of a comparable clinical trial,
￿ Legal authorities’ decision
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latory authorities will be informed about premature clo-
sure of the trial. Furthermore, the Ethics Committee(s)
and competent regulatory authorities themselves may
decide to stop or suspend the trial.
If the trial is closed prematurely, the trial material
such as completed, partially completed, and blank CRFs
will be returned to the coordinating investigator.
All involved investigators have to be informed imme-
diately about a cessation or suspension of the trial. The
decision is binding on all investigators.
Ethics, informed consent, and safety
The final protocol was approved by the University of Hei-
delberg Medical School ethics committee (AFmo-409/
2010). The trial complies with the Helsinki Declaration in
its recent German version, the Medical Association’s pro-
fessional code of conduct, principles of Good Clinical
Practice (GCP) guidelines and the Federal Data Protection
Act. It will be carried out in keeping with local legal and
regulatory requirements. It is also subject to authorization
by the German radiation protection authority (Bundesamt
für Strahlenschutz: = BfS) and Paul-Ehrlich Institute
(: = PEI). Medical confidentiality and Federal Data Protec-
tion Act will be followed. Written informed consent is
obtained from each patient in oral and written form.
Discussion
With the introduction of novel radiotherapy techniques
like IMRT and particle therapy (neutron and carbon ion
therapy), progress has been made toward higher local con-
trol rates in adenoid cystic carcinoma over the last decade.
Compared to neutron RT, carbon ion therapy has only
mild side effects and since the opening of a new dedi-
cated particle therapy facility (HIT) is now permanently
available in Germany. However, we believe treatment
outcome in adenoid cystic carcinoma still leaves room
for improvement. While comparatively chemo-resistant,
radiochemotherapy has not gained establishment as a
standard approach in the treatment of adenoid cystic
carcinoma so far. Since the introduction of the com-
bined radiation and EGFR-inhibition as a standard con-
cept for SCCHN though, targeted therapies such as the
EGFR receptor antibody cetuximab have also gained
interes. In view of the high expression of EGFR expres-
sion in ACC, the combination treatment of IMRT plus
carbon ion boost and cetuximab promises synergistiv
effects of radiation and EGFR inhibition and hence
improvement of local control at the cost of only mild
toxicity. The ACCEPT trial was designed to evaluate
toxicity and efficacy of the combined treatment
approach in a prospective phase I/II trial. To our knowl-
edge, this is the first phase I/II trial combining particle
therapy and targeted therapies.
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